Douglas Esq - Sarepta Therapeutics CEO President
| SRPT Stock | USD 110.50 0.36 0.32% |
CEO
Douglas Esq is CEO President of Sarepta Therapeutics
| Age | 61 |
| Address | 215 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 274 4000 |
| Web | https://www.sarepta.com |
Sarepta Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0151 % which means that it generated a profit of $0.0151 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1227 %, meaning that it created $0.1227 on every $100 dollars invested by stockholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.11 in 2024. At this time, Sarepta Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 39 M in 2024.Similar Executives
| Found 7 records | CEO Age | ||
| FACS MD | PTC Therapeutics | 52 | |
| John Baird | PTC Therapeutics | N/A | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Brian Lian | Viking Therapeutics | 58 | |
| Stuart Peltz | PTC Therapeutics | 64 | |
| William Sibold | Madrigal Pharmaceuticals | 58 | |
| Andrew MD | Akero Therapeutics | 57 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0151 |
Sarepta Therapeutics Leadership Team
Elected by the shareholders, the Sarepta Therapeutics' board of directors comprises two types of representatives: Sarepta Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sarepta. The board's role is to monitor Sarepta Therapeutics' management team and ensure that shareholders' interests are well served. Sarepta Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sarepta Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Ciambrone, Ex Operations | ||
| Dallan Murray, Executive Officer | ||
| Ian Estepan, Executive CFO | ||
| Ryan JD, General VP | ||
| Will Tilton, Head VP | ||
| Douglas Esq, CEO President | ||
| Louise RodinoKlapac, Chief VP | ||
| Alison Nasisi, Executive Officer | ||
| Bilal Arif, Executive Officer | ||
| Diane Berry, Executive Officer | ||
| Ryan Brown, Gen VP | ||
| Mary Jenkins, Sr Relations | ||
| Francesca Nolan, Executive Communications |
Sarepta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sarepta Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0151 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 10.79 B | ||||
| Shares Outstanding | 95.52 M | ||||
| Shares Owned By Insiders | 4.37 % | ||||
| Shares Owned By Institutions | 91.92 % | ||||
| Number Of Shares Shorted | 5.6 M | ||||
| Price To Earning | (20.43) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.